Therefore, the aim of this study was to assess whether EZH2 played a role in myeloid differentiation of human non-APL AML, which had not been previously evaluated, and, if so, whether small molecule inhibitors of EZH2 could be effective in combination with ATRA. The gene discussed is EZH2; the disease is acute promyelocytic leukemia.